* Avid Bioservices Inc CDMO.OQ CDMO.O is expected
to show a
rise in quarterly revenue when it reports results on March 13.
* The Tustin California-based company is expected to report
a
15.3% increase in revenue to $36.318 million from $31.51 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Avid Bioservices
Inc is
for a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Avid
Bioservices
Inc is $22, above its last closing price of $14.82.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Oct. 31 2022 0.00 0.00 -0.02 Missed -300
Jul. 31 2022 0.04 0.04 0.02 Missed -45.5
Apr. 30 2022 0.01 0.01 0.01 Met 0
Jan. 31 2022 0.05 0.04 0.04 Met 0
Oct. 0.03 0.03 0.06 Beat 140
31 2021
Jul. 31 2021 0.04 0.04 0.10 Beat 166.7
Apr. 30 2021 0.00 0.01 -0.04 Missed -900
Jan. 31 2021 -0.03 -0.03 0.01 Beat 133.3
This summary was machine generated March 10 at 21:47 GMT. All
figures in US dollars unless otherwise stated